GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daehan Nupharm Co Ltd (XKRX:054670) » Definitions » Cash Flow from Financing

Daehan Nupharm Co (XKRX:054670) Cash Flow from Financing : ₩31,909 Mil (TTM As of Mar. 2025)


View and export this data going back to 2002. Start your Free Trial

What is Daehan Nupharm Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2025, Daehan Nupharm Co paid ₩0 Mil more to buy back shares than it received from issuing new shares. It received ₩10,224 Mil from issuing more debt. It paid ₩0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent ₩1,404 Mil paying cash dividends to shareholders. It received ₩0 Mil on other financial activities. In all, Daehan Nupharm Co earned ₩8,820 Mil on financial activities for the three months ended in Mar. 2025.


Daehan Nupharm Co Cash Flow from Financing Historical Data

The historical data trend for Daehan Nupharm Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daehan Nupharm Co Cash Flow from Financing Chart

Daehan Nupharm Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,389.67 -2,724.87 -1,383.25 -2,231.69 20,509.68

Daehan Nupharm Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,761.84 8,057.46 9,521.54 5,692.52 8,637.53

Daehan Nupharm Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Daehan Nupharm Co's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

Daehan Nupharm Co's Cash from Financing for the quarter that ended in Mar. 2025 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩31,909 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daehan Nupharm Co  (XKRX:054670) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Daehan Nupharm Co's issuance of stock for the three months ended in Mar. 2025 was ₩0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Daehan Nupharm Co's repurchase of stock for the three months ended in Mar. 2025 was ₩0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Daehan Nupharm Co's net issuance of debt for the three months ended in Mar. 2025 was ₩10,224 Mil. Daehan Nupharm Co received ₩10,224 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Daehan Nupharm Co's net issuance of preferred for the three months ended in Mar. 2025 was ₩0 Mil. Daehan Nupharm Co paid ₩0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Daehan Nupharm Co's cash flow for dividends for the three months ended in Mar. 2025 was ₩-1,404 Mil. Daehan Nupharm Co spent ₩1,404 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Daehan Nupharm Co's other financing for the three months ended in Mar. 2025 was ₩0 Mil. Daehan Nupharm Co received ₩0 Mil on other financial activities.


Daehan Nupharm Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Daehan Nupharm Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Daehan Nupharm Co Business Description

Traded in Other Exchanges
N/A
Address
66 Jeyakgongdan, 1-gil Hyangnameup, Gyeonggi, Hwasung, KOR, 18622
Daehan Nupharm Co Ltd is a South Korea-based company operating in the pharmaceutical sector. It is engaged in producing pharmaceutical products, animal health and nutrition, and bioproducts.

Daehan Nupharm Co Headlines

No Headlines